FENOFIBRATE Side Effects

7011041-2 | Pancreatitis
on Sep 22, 2010 Female patient from UNITED STATES , 69 years of age, weighting 135.0 lb, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: pancreatitis. Fenofibrate dosage: 160mg Daily Po. Patient was hospitalized.

7010847-3 | Anaemia, Beta 2 Microglobulin Increased, Eczema, Pruritus, Skin Lesion
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: anaemia, beta 2 microglobulin increased, eczema (What is eczema?), pruritus, skin lesion on Sep 14, 2010 from GERMANY Additional patient health information: Male patient , 74 years of age, was diagnosed with hyperlipidaemia, anxiety (What is anxiety?), type 2 diabetes mellitus, depression (What is depression?), constipation (What is constipation?) and. Fenofibrate dosage: 200 Mg Daily. During the same period patient was treated with LANSOPRAZOLE (60 Mg Daily) (View Lansoprazole Review and Lansoprazole Label ), XANAX (1 Mg Daily) (View Xanax Review and Xanax Label ), AMAREL (1 Dosage Form Daily) (View Amarel Review and Amarel Label ), GLUCOPHAGE (1700 Mg Daily) (View Glucophage Review and Glucophage Label ), ANAFRANIL (50 Mg Daily) (View Anafranil Review and Anafranil Label ), KARDEGIC (75 Mg Daily) (View Kardegic Review and Kardegic Label ), URBANYL (10 Mg Daily) (View Urbanyl Review and Urbanyl Label ), MACROGOL (3 Dosage Forms Daily) (View Macrogol Review and Macrogol Label ). Patient was hospitalized.

7004270-5 | Dermatitis, Liver Disorder
Adverse event was reported on Sep 06, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: 100 Mg, Unk) was diagnosed with hyperlipidaemia and. Location: GERMANY , 72 years of age, After Fenofibrate was administered, patient had the following side effects: dermatitis, liver disorder. During the same period patient was treated with OLMESARTAN MEDOXOMIL (Unk) (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), AZELNIDIPINE (Unk) (View Azelnidipine Review and Azelnidipine Label ), ALENDRONATE SODIUM HYDRATE (Unk) (View Alendronate Sodium Hydrate Review and Alendronate Sodium Hydrate Label ), ETIZOLAM (Unk) (View Etizolam Review and Etizolam Label ), BROTIZOLAM (Unk) (View Brotizolam Review and Brotizolam Label ).

7000628-9 | Dermatitis, Liver Disorder
on Sep 10, 2010 Female patient from JAPAN , 72 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: dermatitis, liver disorder. Fenofibrate dosage: . During the same period patient was treated with OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), AZELNIDIPINE (View Azelnidipine Review and Azelnidipine Label ), ETIZOLAM (View Etizolam Review and Etizolam Label ), BROTIZOLAM (View Brotizolam Review and Brotizolam Label ).


6976333-1 | Gastrointestinal Haemorrhage, Hypoglycaemia, Liver Disorder, Rhabdomyolysis
on Sep 03, 2010 Male patient from CHINA , 83 years of age, was diagnosed with hyperlipidaemia, arthralgia and was treated with Fenofibrate (View Usage). Patient had the following side effects: gastrointestinal haemorrhage, hypoglycaemia, liver disorder, rhabdomyolysis. Fenofibrate dosage: . During the same period patient was treated with XUEZHIKANG (View Xuezhikang Review and Xuezhikang Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ). Patient was hospitalized.

6975661-3 | Renal Failure, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: renal failure, rhabdomyolysis on Aug 25, 2010 from GERMANY Additional patient health information: Female patient , 45 years of age, was diagnosed with hypertriglyceridaemia, type 2 diabetes mellitus and. Fenofibrate dosage: 200 Mg, Unk. During the same period patient was treated with GLIMEPIRIDE (3 Mg, Unk) (View Glimepiride Review and Glimepiride Label ), METFORMIN (2 G, Unk) (View Metformin Review and Metformin Label ). Patient was hospitalized.

6974234-6 | Ataxia, Axonal Neuropathy, Gait Disturbance, Myalgia
Adverse event was reported on Aug 30, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hypercholesterolaemia and. Location: FRANCE , 69 years of age, Patient experienced the following unwanted or unexpected effects: ataxia (What is ataxia?), axonal neuropathy, gait disturbance, myalgia. During the same period patient was treated with TAHOR (View Tahor Review and Tahor Label ), CRESTOR (View Crestor Review and Crestor Label ), EZETROL (View Ezetrol Review and Ezetrol Label ). Patient was hospitalized.

6971946-5 | Blood Triglycerides Increased, Product Solubility Abnormal, Product Substitution Issue
on Sep 08, 2010 Male patient from UNITED STATES , 64 years of age, weighting 180.8 lb, was diagnosed with blood triglycerides increased and was treated with Fenofibrate (View Usage). Patient had the following side effects: blood triglycerides increased, product solubility abnormal, product substitution issue. Fenofibrate dosage: 160mg Once A Day Orally.

6961665-3 | Gastrointestinal Haemorrhage, Hypoglycaemia, Liver Disorder, Rhabdomyolysis
on Aug 23, 2010 Male patient from CHINA , 83 years of age, was diagnosed with hyperlipidaemia, arthralgia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: gastrointestinal haemorrhage, hypoglycaemia, liver disorder, rhabdomyolysis. Fenofibrate dosage: . During the same period patient was treated with MELOXICAM (View Meloxicam Review and Meloxicam Label ). Patient was hospitalized.

6960953-4 | Cytolytic Hepatitis, Jaundice
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: cytolytic hepatitis, jaundice (What is jaundice?) on Aug 24, 2010 from FRANCE Additional patient health information: Male patient , 32 years of age, was diagnosed with hypertriglyceridaemia and. Fenofibrate dosage: . During the same period patient was treated with LEVOYHYROX 50 (View Levoyhyrox 50 Review and Levoyhyrox 50 Label ), INIPOMP (View Inipomp Review and Inipomp Label ). Patient was hospitalized.

6960577-9 | Blood Creatinine Increased, Gastrointestinal Haemorrhage, Liver Disorder, Pain In Extremity, Rhabdomyolysis
Adverse event was reported on Aug 27, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hyperlipidaemia, arthralgia and. Location: CHINA , 83 years of age, Patient had the following side effects: blood creatinine increased, gastrointestinal haemorrhage, liver disorder, pain in extremity, rhabdomyolysis. During the same period patient was treated with XUEZHIKANG (View Xuezhikang Review and Xuezhikang Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ). Patient was hospitalized.

6957356-5 | Hepatitis
on Aug 18, 2010 Male patient from UNITED KINGDOM , 56 years of age, was diagnosed with diabetes mellitus and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatitis (What is hepatitis?). Fenofibrate dosage: . During the same period patient was treated with GLUCOPHAGE SR (500 Mg, Bid) (View Glucophage Sr Review and Glucophage Sr Label ), LIPITOR (View Lipitor Review and Lipitor Label ), METFORMIN (View Metformin Review and Metformin Label ), NATEGLINIDE (View Nateglinide Review and Nateglinide Label ), PIOGLITAZONE (View Pioglitazone Review and Pioglitazone Label ).

6956818-4 | Blood Creatinine Increased, Gastrointestinal Haemorrhage, Liver Disorder, Pain In Extremity, Rhabdomyolysis
on Aug 20, 2010 Female patient from CHINA , 83 years of age, was diagnosed with hyperlipidaemia, arthralgia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, gastrointestinal haemorrhage, liver disorder, pain in extremity, rhabdomyolysis. Fenofibrate dosage: . During the same period patient was treated with MELOXICAM (View Meloxicam Review and Meloxicam Label ). Patient was hospitalized.

6944390-4 | Renal Failure, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: renal failure, rhabdomyolysis on Aug 20, 2010 from TURKEY Additional patient health information: Female patient , 45 years of age, was diagnosed with hypertriglyceridaemia and. Fenofibrate dosage: 200 Mg, Unk.

6936954-9 | Neuropathy Peripheral
Adverse event was reported on Aug 13, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: ) . Location: FRANCE , 71 years of age, After Fenofibrate was administered, patient had the following side effects: neuropathy peripheral. Patient was hospitalized.

6936890-8 | Cholestasis, Liver Function Test Abnormal
on Aug 13, 2010 Female patient from JAPAN , 60 years of age, weighting 105.8 lb, was diagnosed with dyslipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: cholestasis, liver function test abnormal. Fenofibrate dosage: . During the same period patient was treated with BEZAFIBRATE (View Bezafibrate Review and Bezafibrate Label ), ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ).

6930997-7 | Hepatic Function Abnormal
on Aug 04, 2010 Female patient from JAPAN , 62 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 200 Mg Daily. During the same period patient was treated with BENIDIPINE HYDROCHLORIDE (View Benidipine Hydrochloride Review and Benidipine Hydrochloride Label ), RISEDRONATE SODIUM (View Risedronate Sodium Review and Risedronate Sodium Label ), IMIDAPRIL HYDROCHLORIDE (View Imidapril Hydrochloride Review and Imidapril Hydrochloride Label ). Patient was hospitalized.

6929128-9 | Liver Disorder
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: liver disorder on Aug 04, 2010 from JAPAN Additional patient health information: Male patient , 59 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with BEZAFIBRATE (View Bezafibrate Review and Bezafibrate Label ).

6928796-5 | Jaundice, Liver Disorder
Adverse event was reported on Aug 04, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hyperlipidaemia and. Location: GERMANY , 71 years of age, Patient experienced the following unwanted or unexpected effects: jaundice (What is jaundice?), liver disorder. During the same period patient was treated with FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6928514-0 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Urea Increased, Gamma-glutamyltransferase Increased
on Aug 04, 2010 Male patient from GERMANY , 51 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood creatinine increased, blood urea increased, gamma-glutamyltransferase increased. Fenofibrate dosage: .

6918242-X | Blood Albumin Decreased, Blood Calcium Decreased, Haemoglobin Decreased, Renal Failure Acute, Rhabdomyolysis
on Jul 27, 2010 Male patient from TURKEY , 74 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: blood albumin decreased, blood calcium decreased, haemoglobin decreased, renal failure acute, rhabdomyolysis. Fenofibrate dosage: 200 Mg, Unk.

6916337-8 | Renal Failure Acute, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute, rhabdomyolysis on Jul 27, 2010 from TURKEY Additional patient health information: Male patient , 69 years of age, was diagnosed with hypertriglyceridaemia, hypertension and. Fenofibrate dosage: 200 Mg, Unk. During the same period patient was treated with METOPROLOL (50 Mg, Unk) (View Metoprolol Review and Metoprolol Label ), VALSARTAN/HYDROCHLOROTHIAZIDEVALSARTAN (160 Mg+25 Mg) (View Valsartan/hydrochlorothiazidevalsartan Review and Valsartan/hydrochlorothiazidevalsartan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6915631-4 | Liver Disorder
Adverse event was reported on May 04, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 134 Mg, Unk) was diagnosed with hyperlipidaemia and. Location: GERMANY , 55 years of age, Patient had the following side effects: liver disorder. During the same period patient was treated with GLIMEPIRIDE (Unk) (View Glimepiride Review and Glimepiride Label ), MIGLITOL (Unk) (View Miglitol Review and Miglitol Label ), PIOGLITAZONE (Unk) (View Pioglitazone Review and Pioglitazone Label ).

6913431-2 | Bone Pain, Dysstasia, Headache, Myalgia
on Aug 05, 2010 Female patient from UNITED STATES , 63 years of age, weighting 196.0 lb, was diagnosed with blood cholesterol increased and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: bone pain, dysstasia, headache (What is headache?), myalgia. Fenofibrate dosage: 160 Mg 1 Tablet/day At Supper Round W/ Klx And 171.

6910125-4 | Liver Function Test Abnormal
on Jul 30, 2010 Female patient from , 60 years of age, was diagnosed with dyslipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: liver function test abnormal. Fenofibrate dosage: Daily. During the same period patient was treated with BEZAFIBRATE (Daily) (View Bezafibrate Review and Bezafibrate Label ), ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ).

6907349-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Liver Disorder
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, liver disorder on Jul 16, 2010 from JAPAN Additional patient health information: Male patient , 59 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: 100 Mg, Oral. During the same period patient was treated with BENZAFIBRATE (BEZAFIBRATE) (View Benzafibrate (bezafibrate) Review and Benzafibrate (bezafibrate) Label ).

6899580-6 | Liver Disorder
Adverse event was reported on Jul 16, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 100 Mg, Unk) was diagnosed with hyperlipidaemia and. Location: GERMANY , 59 years of age, After Fenofibrate was administered, patient had the following side effects: liver disorder. During the same period patient was treated with BEZAFIBRATE (Unk) (View Bezafibrate Review and Bezafibrate Label ).

6897432-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Urea Increased, Gamma-glutamyltransferase Increased
on Jul 14, 2010 Male patient from JAPAN , 51 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood creatinine increased, blood urea increased, gamma-glutamyltransferase increased. Fenofibrate dosage: 100 Mg, Oral.

6897339-7 | Erythema Multiforme
on Jul 14, 2010 Male patient from JAPAN , 84 years of age, was treated with Fenofibrate (View Usage). Patient had the following side effects: erythema multiforme. Fenofibrate dosage: Oral.

6897336-1 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Liver Disorder
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, liver disorder on Jul 14, 2010 from JAPAN Additional patient health information: Female patient , 57 years of age, . Fenofibrate dosage: Oral.

6894417-3 | Hepatic Function Abnormal
Adverse event was reported on Jul 13, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: 200 Mg, Oral) was diagnosed with hyperlipidaemia and. Location: JAPAN , 62 years of age, Patient experienced the following unwanted or unexpected effects: hepatic function abnormal. During the same period patient was treated with BENIDIPINE HYDROCHLORIDE (BENIDIPINE HYDROCHLORIDE) (View Benidipine Hydrochloride (benidipine Hydrochloride) Review and Benidipine Hydrochloride (benidipine Hydrochloride) Label ), SODIUM RISEDRONATE HYDRATE (SODIUM RISEDRONATE HYDRATE) (View Sodium Risedronate Hydrate (sodium Risedronate Hydrate) Review and Sodium Risedronate Hydrate (sodium Risedronate Hydrate) Label ), IMIDAPRIL HYDROCHLORIDE (IMIDAPRIL HYDROCHLORIDE) (View Imidapril Hydrochloride (imidapril Hydrochloride) Review and Imidapril Hydrochloride (imidapril Hydrochloride) Label ). Patient was hospitalized.

6894188-0 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Urea Increased, Gamma-glutamyltransferase Increased
on Jul 14, 2010 Male patient from JAPAN , 51 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood creatinine increased, blood urea increased, gamma-glutamyltransferase increased. Fenofibrate dosage: 100 Mg, Unk.

6894184-3 | Liver Disorder
on Jul 14, 2010 Female patient from GERMANY , 57 years of age, was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: liver disorder. Fenofibrate dosage: Unk.

6894180-6 | Erythema Multiforme
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: erythema multiforme on Jul 14, 2010 from JAPAN Additional patient health information: Male patient , 84 years of age, . Fenofibrate dosage: Unk.

6894009-6 | Blood Pressure Decreased, Erythema Multiforme, Hyponatraemia
Adverse event was reported on Jul 12, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: 100 Mg, Unk) was diagnosed with hyperlipidaemia and. Location: GERMANY , 68 years of age, Patient had the following side effects: blood pressure decreased, erythema multiforme, hyponatraemia. During the same period patient was treated with ROSUVASTATIN CALCIUM (Unk) (View Rosuvastatin Calcium Review and Rosuvastatin Calcium Label ).

6893725-X | Liver Disorder
on Jul 16, 2010 Male patient from GERMANY , 59 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: liver disorder. Fenofibrate dosage: 100 Mg, Unk. During the same period patient was treated with BEZAFIBRATE (Unk) (View Bezafibrate Review and Bezafibrate Label ).

6884486-9 | Blood Pressure Decreased, Erythema Multiforme, Hyponatraemia
on Jul 12, 2010 Female patient from JAPAN , 68 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, erythema multiforme, hyponatraemia. Fenofibrate dosage: 100 Mg, Oral. During the same period patient was treated with ROSUVASTATIN CALCIUM (View Rosuvastatin Calcium Review and Rosuvastatin Calcium Label ).

6884185-3 | Hepatic Function Abnormal
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal on Jul 21, 2010 from JAPAN Additional patient health information: Male patient , 60 years of age, was diagnosed with low density lipoprotein increased and. Fenofibrate dosage: 134mg Daily. During the same period patient was treated with DILTIAZEM HYDROCHLORIDE (View Diltiazem Hydrochloride Review and Diltiazem Hydrochloride Label ), DAI KENCHU TO (View Dai-kenchu-to Review and Dai-kenchu-to Label ), SENNA LEAF (View Senna Leaf Review and Senna Leaf Label ), FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ).

6883973-7 | Liver Disorder
Adverse event was reported on Jul 19, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: ) . Location: JAPAN , 57 years of age, After Fenofibrate was administered, patient had the following side effects: liver disorder.

6882892-X | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Urea Increased, Gamma-glutamyltransferase Increased
on Jul 19, 2010 Male patient from GERMANY , 51 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood creatinine increased, blood urea increased, gamma-glutamyltransferase increased. Fenofibrate dosage: .

6881936-9 | Erythema Multiforme
on Jul 19, 2010 Male patient from JAPAN , 84 years of age, was treated with Fenofibrate (View Usage). Patient had the following side effects: erythema multiforme. Fenofibrate dosage: .

6880893-9 | Liver Disorder
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: liver disorder on Jul 21, 2010 from JAPAN Additional patient health information: Male patient , 59 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with BEZAFIBRATE (View Bezafibrate Review and Bezafibrate Label ).

6878709-X | Cholestasis
Adverse event was reported on Jul 19, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: Daily) was diagnosed with dyslipidaemia and. Location: , 60 years of age, Patient experienced the following unwanted or unexpected effects: cholestasis. During the same period patient was treated with BEZAFIBRATE (Daily) (View Bezafibrate Review and Bezafibrate Label ), ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ).

6872561-4 | Hepatic Function Abnormal
on Jul 15, 2010 Female patient from JAPAN , 62 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 200 Mg Daily. During the same period patient was treated with BENIDIPINE HYDROCHLORIDE (View Benidipine Hydrochloride Review and Benidipine Hydrochloride Label ), RISEDRONATE SODIUM (View Risedronate Sodium Review and Risedronate Sodium Label ), IMIDAPRIL HYDROCHLORIDE (View Imidapril Hydrochloride Review and Imidapril Hydrochloride Label ). Patient was hospitalized.

6872257-9 | Hepatic Function Abnormal
on Jul 14, 2010 Male patient from JAPAN , 60 years of age, was diagnosed with low density lipoprotein increased and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 134mg Daily. During the same period patient was treated with DILTIAZEM HYDROCHLORIDE (View Diltiazem Hydrochloride Review and Diltiazem Hydrochloride Label ), DAI KENCHU TO (View Dai-kenchu-to Review and Dai-kenchu-to Label ), SENNA LEAF (View Senna Leaf Review and Senna Leaf Label ), FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ).

6871200-6 | Blood Pressure Decreased, Erythema Multiforme, Hyponatraemia
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, erythema multiforme, hyponatraemia on Jul 15, 2010 from JAPAN Additional patient health information: Female patient , 68 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with ROSUVASTATIN CALCIUM (View Rosuvastatin Calcium Review and Rosuvastatin Calcium Label ).

6840658-0 | Renal Failure Acute, Rhabdomyolysis
Adverse event was reported on Jul 13, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 145 Mg Every Day Po) was diagnosed with hyperlipidaemia and. Location: UNITED STATES , 61 years of age, weighting 220.0 lb, Patient had the following side effects: renal failure acute, rhabdomyolysis. During the same period patient was treated with PRAVASTATIN (40 Mg Every Day Po) (View Pravastatin Review and Pravastatin Label ).

6816886-7 | Duodenal Ulcer Haemorrhage
on Jun 22, 2010 Male patient from GERMANY , 55 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: duodenal ulcer haemorrhage. Fenofibrate dosage: 134 Mg, Unk. During the same period patient was treated with DILTIAZEM HYDROCHLORIDE (View Diltiazem Hydrochloride Review and Diltiazem Hydrochloride Label ), UBIDECARENONE (View Ubidecarenone Review and Ubidecarenone Label ), METILDIGOXIN (View Metildigoxin Review and Metildigoxin Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ), CIBENZOLINE SUCCINATE (View Cibenzoline Succinate Review and Cibenzoline Succinate Label ). Patient was hospitalized.

6810251-4 | Neuropathy Peripheral
on Jun 17, 2010 Female patient from UNITED STATES , 69 years of age, was diagnosed with dyslipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: neuropathy peripheral. Fenofibrate dosage: 145mg.

6800742-4 | Erythema Multiforme
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: erythema multiforme on Jun 15, 2010 from GERMANY Additional patient health information: Female patient , 68 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: Unk. During the same period patient was treated with ROSUVASTATIN (Unk) (View Rosuvastatin Review and Rosuvastatin Label ).